Table of Contents
Breaking Advances
Reviews
- ReviewsArman Jahangiri, Manish K. Aghi and W. Shawn CarbonellCancer Res January 1 2014 74 (1) 3-7; DOI:10.1158/0008-5472.CAN-13-1742
- Reviews | AuthorChoiceToru Atsumi, Rajeev Singh, Lavannya Sabharwal, Hidenori Bando, Jie Meng, Yasunobu Arima, Moe Yamada, Masaya Harada, Jing-Jing Jiang, Daisuke Kamimura, Hideki Ogura, Toshio Hirano and Masaaki MurakamiCancer Res January 1 2014 74 (1) 8-14; DOI:10.1158/0008-5472.CAN-13-2322
Priority Reports
- Priority Reports | AuthorChoiceHailing Cheng, Pixu Liu, Fan Zhang, Erbo Xu, Lynn Symonds, Carolynn E. Ohlson, Roderick T. Bronson, Sauveur-Michel Maira, Emmanuelle Di Tomaso, Jane Li, Andrea P. Myers, Lewis C. Cantley, Gordon B. Mills and Jean J. ZhaoCancer Res January 1 2014 74 (1) 15-23; DOI:10.1158/0008-5472.CAN-13-0544
These findings suggest insights into the basis for development of an aggressive form of endometrial cancer that is driven by deregulated mTOR signaling.
- Priority ReportsDamya Laoui, Eva Van Overmeire, Giusy Di Conza, Chiara Aldeni, Jiri Keirsse, Yannick Morias, Kiavash Movahedi, Isabelle Houbracken, Elio Schouppe, Yvon Elkrim, Oussama Karroum, Bénédicte Jordan, Peter Carmeliet, Conny Gysemans, Patrick De Baetselier, Massimiliano Mazzone and Jo A. Van GinderachterCancer Res January 1 2014 74 (1) 24-30; DOI:10.1158/0008-5472.CAN-13-1196
This study challenges the notion that TAMs are a primary beneficiary of hypoxia in the tumor microenvironment, shifting attention to M2 macrophages to explain how the poorly organized vasculature of tumors promotes malignant progression.
- Priority ReportsJamin D. Steffen, Renee M. Tholey, Marie-France Langelier, Jamie L. Planck, Matthew J. Schiewer, Shruti Lal, Nikolai A. Bildzukewicz, Charles J. Yeo, Karen E. Knudsen, Jonathan R. Brody and John M. PascalCancer Res January 1 2014 74 (1) 31-37; DOI:10.1158/0008-5472.CAN-13-1701
This study establishes a new strategy to selectively inhibit the DNA repair enzyme PARP-1, a clinically validated target for cancer treatment.
- Priority ReportsAmudhan Venkateswaran, Konjeti R. Sekhar, Daniel S. Levic, David B. Melville, Travis A. Clark, Witold M. Rybski, Alexandra J. Walsh, Melissa C. Skala, Peter A. Crooks, Ela W. Knapik and Michael L. FreemanCancer Res January 1 2014 74 (1) 38-43; DOI:10.1158/0008-5472.CAN-13-1981
ENOX1 may offer an appealing new antiangiogenic target for cancer therapy based on its role in influencing sensitivity to radiotherapy and DNA-damaging cytotoxic agents.
Integrated Systems and Technologies
- Integrated Systems and TechnologiesJung Sun Yoo, Sung-Chan Lee, Zhi Yen Jow, Pamela Yun Xiang Koh and Young-Tae ChangCancer Res January 1 2014 74 (1) 44-55; DOI:10.1158/0008-5472.CAN-13-2129
These findings illustrate an intraoperative platform technology to improve lymph node staging, providing fluorescent guidance during cancer surgery that might reduce complications such as lymphedema.
- Integrated Systems and TechnologiesZayar P. Khin, Maria L.C. Ribeiro, Timothy Jacobson, Lori Hazlehurst, Lia Perez, Rachid Baz, Kenneth Shain and Ariosto S. SilvaCancer Res January 1 2014 74 (1) 56-67; DOI:10.1158/0008-5472.CAN-13-2397
This study describes a system to test cancer cells from patients against a panel of drugs and to generate computational models with the potential to inform the best treatment for individual patients.
Microenvironment and Immunology
- Microenvironment and ImmunologyAna I. Romero, Nathalie Chaput, Vichnou Poirier-Colame, Sylvie Rusakiewicz, Nicolas Jacquelot, Kariman Chaba, Erwan Mortier, Yannick Jacques, Sophie Caillat-Zucman, Caroline Flament, Anne Caignard, Meriem Messaoudene, Anne Aupérin, Philippe Vielh, Philippe Dessen, Camillo Porta, Christine Mateus, Maha Ayyoub, Danila Valmori, Alexander Eggermont, Caroline Robert and Laurence ZitvogelCancer Res January 1 2014 74 (1) 68-80; DOI:10.1158/0008-5472.CAN-13-1186
These important findings suggest that the multikinase inhibitor sorafenib acts as an immunotherapy to modulate T cells in the cancer patient, inducing a rare but clinically important subset of T cells that has been associated with prolonged survival in metastatic melanoma patients.
- Microenvironment and ImmunologyMeriem Messaoudene, Giulia Fregni, Emmanuelle Fourmentraux-Neves, Johan Chanal, Eve Maubec, Sarra Mazouz-Dorval, Benoit Couturaud, Angelique Girod, Xavier Sastre-Garau, Sebastien Albert, Charles Guédon, Lydia Deschamps, Delphine Mitilian, Isabelle Cremer, Nicolas Jacquelot, Sylvie Rusakiewicz, Laurence Zitvogel, Marie-Francoise Avril and Anne CaignardCancer Res January 1 2014 74 (1) 81-92; DOI:10.1158/0008-5472.CAN-13-1303
Metastatic lymph nodes from melanoma patients contain a unique subset of natural killer cells endowed with high cytotoxic potential toward melanoma cells, the activation of which can be realized by exposure to IL-2 or IL-15.
- Microenvironment and ImmunologyKo Kudo, Chihaya Imai, Paolo Lorenzini, Takahiro Kamiya, Koji Kono, Andrew M. Davidoff, Wee Joo Chng and Dario CampanaCancer Res January 1 2014 74 (1) 93-103; DOI:10.1158/0008-5472.CAN-13-1365
This report describes a means to endow T lymphocytes with antibody-dependent cell cytotoxicity, offering a powerful strategy to improve antibody-based immunotherapies for human cancer.
- Microenvironment and ImmunologyDarya Alizadeh, Malika Trad, Neale T. Hanke, Claire B. Larmonier, Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis and Nicolas LarmonierCancer Res January 1 2014 74 (1) 104-118; DOI:10.1158/0008-5472.CAN-13-1545
This study shows how a traditional cytotoxic cancer drug can be used to reverse myeloid immunosuppression in the tumor microenvironment and to enhance the efficacy of adoptively transferred T cells that attack tumors, creating a highly effective immunochemotherapy regimen.
- Microenvironment and ImmunologyDario Sangiolo, Giulia Mesiano, Loretta Gammaitoni, Valeria Leuci, Maja Todorovic, Lidia Giraudo, Cristina Cammarata, Carmine Dell'Aglio, Lorenzo D'Ambrosio, Alberto Pisacane, Ivana Sarotto, Sara Miano, Ivana Ferrero, Fabrizio Carnevale-Schianca, Ymera Pignochino, Francesco Sassi, Andrea Bertotti, Wanda Piacibello, Franca Fagioli, Massimo Aglietta and Giovanni GrignaniCancer Res January 1 2014 74 (1) 119-129; DOI:10.1158/0008-5472.CAN-13-1559
This report offers a preclinical proof-of-concept for a novel type of cellular immunotherapy to attack untreatable metastatic sarcomas, which continue to pose a major clinical challenge.
- Microenvironment and Immunology | AuthorChoiceViviana Vallacchi, Elisabetta Vergani, Chiara Camisaschi, Paola Deho, Antonello D. Cabras, Marialuisa Sensi, Loris De Cecco, Niccolò Bassani, Federico Ambrogi, Antonino Carbone, Federica Crippa, Barbara Vergani, Paola Frati, Flavio Arienti, Roberto Patuzzo, Antonello Villa, Elia Biganzoli, Silvana Canevari, Mario Santinami, Chiara Castelli, Licia Rivoltini and Monica RodolfoCancer Res January 1 2014 74 (1) 130-140; DOI:10.1158/0008-5472.CAN-13-1672
By deepening the evidence that sentinel lymph nodes help direct tumoral immunosuppression, this study identifies an immune activation marker associated with poor prognosis that might allow targeting by a drug recently approved by the FDA.
- Microenvironment and ImmunologyPingyan Cheng, Vinit Kumar, Hao Liu, Je-In Youn, Mayer Fishman, Simon Sherman and Dmitry GabrilovichCancer Res January 1 2014 74 (1) 141-152; DOI:10.1158/0008-5472.CAN-13-1686
These results suggest new insights into how abnormal myeloid cells accumulate in tumors, with possible implications for therapy of cancers driven by Notch.
- Microenvironment and Immunology | AuthorChoiceInhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer ImmunotherapyStephen Mok, Richard C. Koya, Christopher Tsui, Jingying Xu, Lídia Robert, Lily Wu, Thomas G. Graeber, Brian L. West, Gideon Bollag and Antoni RibasCancer Res January 1 2014 74 (1) 153-161; DOI:10.1158/0008-5472.CAN-13-1816
These findings suggest an important new use for inhibitors of a myeloid cell receptor that is responsible for recruiting immune-suppressive cells into tumors as a strategy to enhance adoptive T-cell immunotherapy.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyAdam J. MacNeil, Shun-Chang Jiao, Lori A. McEachern, Yong Jun Yang, Amanda Dennis, Haiming Yu, Zhaolin Xu, Jean S. Marshall and Tong-Jun LinCancer Res January 1 2014 74 (1) 162-172; DOI:10.1158/0008-5472.CAN-13-1310
These findings reveal the functional significance of a MAPK kinase as a tumor suppressor in breast cancer, improving understanding of the dynamic role of the MAPK pathway in tumor progression.
- Molecular and Cellular PathobiologyTrenis D. Palmer, Carlos H. Martínez, Catalina Vasquez, Katie E. Hebron, Celestial Jones-Paris, Shanna A. Arnold, Susanne M. Chan, Venu Chalasani, Jose A. Gomez-Lemus, Andrew K. Williams, Joseph L. Chin, Giovanna A. Giannico, Tatiana Ketova, John D. Lewis and Andries ZijlstraCancer Res January 1 2014 74 (1) 173-187; DOI:10.1158/0008-5472.CAN-13-0275
A common component of cell surface scaffolds that organize cell motility and physiology is altered during oncogenesis in a manner that confers cancer cells with aggressive qualities, causing poor outcomes.
- Molecular and Cellular PathobiologyAzusa Tanaka-Nakanishi, Jun-ichirou Yasunaga, Ken Takai and Masao MatsuokaCancer Res January 1 2014 74 (1) 188-200; DOI:10.1158/0008-5472.CAN-13-0436
These findings reveal mechanistic insights into the molecular pathogenicity of the cancer-causing human virus HTLV-1 by defining the antiapoptotic effects of one of its key gene products.
- Molecular and Cellular PathobiologySejeong Shin, Laura Wolgamott, Philippe P. Roux and Sang-Oh YoonCancer Res January 1 2014 74 (1) 201-211; DOI:10.1158/0008-5472.CAN-13-1175
These findings suggest a rationale for a generalized strategy to treat human cancers by blocking a pivotal kinase-regulated step in mRNA translation.
- Molecular and Cellular PathobiologyMaohua Xie, Yun Yen, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri, Walter J. Curran, Paul W. Doetsch and Xingming DengCancer Res January 1 2014 74 (1) 212-223; DOI:10.1158/0008-5472.CAN-13-1536-T
These findings uncover a novel link between Bcl2 function and the progress of DNA replication, with potential implications on how to apply Bcl2 inhibitors in the clinic for cancer treatment.
- Molecular and Cellular Pathobiology | AuthorChoiceShivendra Kishore, Salvatore Piscuoglio, Michal B. Kovac, Annette Gylling, Friedel Wenzel, Francesca Trapani, Hans Joerg Altermatt, Valentina Mele, Giancarlo Marra, Päivi Peltomäki, Luigi Terracciano, Mihaela Zavolan and Karl HeinimannCancer Res January 1 2014 74 (1) 224-234; DOI:10.1158/0008-5472.CAN-13-2100
This study identifies a novel genetic locus that is fully informative and accurate in detecting mismatch-repair deficient cancers, with major implications for routine daily practice in the clinic.
Prevention and Epidemiology
- Prevention and EpidemiologyCari M. Kitahara, Michael Gamborg, Amy Berrington de González, Thorkild I.A. Sørensen and Jennifer L. BakerCancer Res January 1 2014 74 (1) 235-242; DOI:10.1158/0008-5472.CAN-13-2228
Findings from this large study suggest that early-life exposures affecting childhood height and weight may increase the risk of thyroid cancer later in life.
- Prevention and EpidemiologyHaitao Li, Feng Zhu, Hanyong Chen, Ka Wing Cheng, Tatyana Zykova, Naomi Oi, Ronald A. Lubet, Ann M. Bode, Mingfu Wang and Zigang DongCancer Res January 1 2014 74 (1) 243-252; DOI:10.1158/0008-5472.CAN-13-2245
COX-1 plays a critical role in human colorectal carcinogenesis and a rationale is presented here to target its activity as a strategy to prevent colorectal cancer.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyJin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, Bu Man Park, Eunhye Park, Jong Hwan Bae, Chang-Min Choi and Jae Cheol LeeCancer Res January 1 2014 74 (1) 253-262; DOI:10.1158/0008-5472.CAN-13-1103
A new drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance may be particularly useful for treatment of acquired resistance to EGFR inhibitors.
- Therapeutics, Targets, and Chemical BiologyLaurentiu M. Pop, Stephen Barman, Chunli Shao, Jonathan C. Poe, Guglielmo M. Venturi, John M. Shelton, Iliodora V. Pop, David E. Gerber, Luc Girard, Xiao-yun Liu, Carmen Behrens, Jaime Rodriguez-Canales, Hui Liu, Ignacio I. Wistuba, James A. Richardson, John D. Minna, Thomas F. Tedder and Ellen S. VitettaCancer Res January 1 2014 74 (1) 263-271; DOI:10.1158/0008-5472.CAN-13-1436
These findings challenge a previous study reporting widespread overexpression of the cell surface protein CD22 in lung cancers, for which it had been suggested as a new target for immunotherapy.
- Therapeutics, Targets, and Chemical BiologyRandy S. Schrecengost, Jeffry L. Dean, Jonathan F. Goodwin, Matthew J. Schiewer, Mark W. Urban, Timothy J. Stanek, Robyn T. Sussman, Jessica L. Hicks, Ruth C. Birbe, Rossitza A. Draganova-Tacheva, Tapio Visakorpi, Angelo M. DeMarzo, Steven B. McMahon and Karen E. KnudsenCancer Res January 1 2014 74 (1) 272-286; DOI:10.1158/0008-5472.CAN-13-1954
These findings define a deubiquitinating enzyme as an important positive modifier of tumor progression, providing a strong rationale for it as an appealing therapeutic target to treat advanced cancers.
- Therapeutics, Targets, and Chemical Biology | Free ArticleIlirjana Bajrami, Jessica R. Frankum, Asha Konde, Rowan E. Miller, Farah L. Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper, Lina Chen, Iwanka Kozarewa, Ioannis Assiotis, Kerry Fenwick, Rachael Natrajan, Christopher J. Lord and Alan AshworthCancer Res January 1 2014 74 (1) 287-297; DOI:10.1158/0008-5472.CAN-13-2541
These important findings suggest much greater utility for cancer treatment with PARP inhibitors than appreciated previously and also reveal a clinically relevant biomarker that is likely to be important for predicting PARP inhibitor responses.
- Therapeutics, Targets, and Chemical BiologyDong Hoon Shin, Yong-Joon Choi and Jong-Wan ParkCancer Res January 1 2014 74 (1) 298-308; DOI:10.1158/0008-5472.CAN-13-2620
This study provides a preclinical proof-of-concept to target the SIRT1–AMPK pathway as a strategy to overcome hypoxia-induced chemoresistance in lung cancer, with potentially broader implications for solid tumors generally.
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyJanine M. Buonato and Matthew J. LazzaraCancer Res January 1 2014 74 (1) 309-319; DOI:10.1158/0008-5472.CAN-12-4721
Combining targeted inhibitors of MEK or ERK with EGFR inhibitors not only restrains the epithelial–mesenchymal transition in lung cancer cells associated with drug resistance but also overcomes the resistance to EGFR-targeted therapy, suggesting immediate applications in the clinic, where this issue is both timely and important.
- Tumor and Stem Cell Biology | AuthorChoiceHemant K. Bid, Ryan D. Roberts, Maren Cam, Anthony Audino, Raushan T. Kurmasheva, Jiayuh Lin, Peter J. Houghton and Hakan CamCancer Res January 1 2014 74 (1) 320-329; DOI:10.1158/0008-5472.CAN-13-0894
These findings reveal a key support to tumor angiogenesis in two aggressive childhood cancers, with implications for understanding progression and potential treatments.
- Tumor and Stem Cell BiologyYi Luo, Junya Yoneda, Hitoshi Ohmori, Takamitsu Sasaki, Kazutaka Shimbo, Sachise Eto, Yumiko Kato, Hiroshi Miyano, Tsuyoshi Kobayashi, Tomonori Sasahira, Yoshitomo Chihara and Hiroki KuniyasuCancer Res January 1 2014 74 (1) 330-340; DOI:10.1158/0008-5472.CAN-13-1052
This important study shows how budding tumors recruit muscle to supply glutamine to cancer cells as an energy source through the release of HMGB1, a proinflammatory autophagy-inducing molecule that influences muscle physiology.
- Tumor and Stem Cell BiologyCleo Yi-Fang Lee, Yuan Lin, Scott V. Bratman, Weiguo Feng, Angera H. Kuo, Ferenc A. Scheeren, Jesse M. Engreitz, Sushama Varma, Robert B. West and Maximilian DiehnCancer Res January 1 2014 74 (1) 341-352; DOI:10.1158/0008-5472.CAN-13-1055
This important work shows why HER2-targeting therapies might benefit a considerably larger number of breast cancer patients than they currently reach.
- Tumor and Stem Cell BiologyZlatko Smole, Claudio R. Thoma, Kathryn T. Applegate, Maria Duda, Katrin L. Gutbrodt, Gaudenz Danuser and Wilhelm KrekCancer Res January 1 2014 74 (1) 353-362; DOI:10.1158/0008-5472.CAN-13-1334
NF2 regulates the dynamic instability of microtubules, a function shared with the tumor suppressor VHL that also helps block aberrant microtubule-mediated processes needed for tumorigenesis.
- Tumor and Stem Cell BiologySumaiyah K. Rehman, Shau-Hsuan Li, Shannon L. Wyszomierski, Qingfei Wang, Ping Li, Ozgur Sahin, Yi Xiao, Siyuan Zhang, Yan Xiong, Jun Yang, Hai Wang, Hua Guo, Jitao D. Zhang, Daniel Medina, William J. Muller and Dihua YuCancer Res January 1 2014 74 (1) 363-373; DOI:10.1158/0008-5472.CAN-13-2016
This study establishes a powerful oncogenic function for a factor with a broad-acting modifier role in signaling that is commonly overexpressed in breast cancer cells, with potential implications for etiology, diagnosis, and prognosis.
- Tumor and Stem Cell BiologyLaura R. Bohrer, Pavlina Chuntova, Lindsey K. Bade, Thomas C. Beadnell, Ronald P. Leon, Nicholas J. Brady, Yungil Ryu, Jodi E. Goldberg, Stephen C. Schmechel, Joseph S. Koopmeiners, James B. McCarthy and Kathryn L. SchwertfegerCancer Res January 1 2014 74 (1) 374-386; DOI:10.1158/0008-5472.CAN-13-2469
Aberrant growth factor receptor signaling in tumor cells leads to profound changes in their microenvironment that can promote therapeutic resistance and posttreatment relapses.
- Tumor and Stem Cell Biology | AuthorChoicePatrick J. Halvey, Xiaojing Wang, Jing Wang, Ajaz A. Bhat, Punita Dhawan, Ming Li, Bing Zhang, Daniel C. Liebler and Robbert J.C. SlebosCancer Res January 1 2014 74 (1) 387-397; DOI:10.1158/0008-5472.CAN-13-2488
Global proteomic profiling reveals adaptations to mutations in DNA mismatch repair that occur in certain colon cancers that were not previously appreciated, providing a broader basis to mechanistically interpret phenotypes seen in colon cancer patients.
Volume 74, Issue 1